Literature DB >> 27404896

Prognostic variables in high-risk cutaneous squamous cell carcinoma: a review.

Judy Cheng1, Shaofeng Yan2.   

Abstract

Cutaneous squamous cell carcinoma (SCC) is a growing public health problem in the United States. A subset of high-risk SCC exhibits a more aggressive clinical trajectory including increased local recurrence and lymph node metastasis. However, there are no universally accepted criteria to help define and manage these patients. This review provides an overview of the high-risk features of cutaneous SCC, prognostic stratification of various staging systems and treatment options. It further examines the prognostic factors influencing the staging of cutaneous head and neck SCC.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cutaneous squamous cell carcinoma; management; prognosis; staging

Mesh:

Year:  2016        PMID: 27404896     DOI: 10.1111/cup.12766

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  12 in total

1.  Differences between epithelial and mesenchymal human tongue cancer cell lines in experimental metastasis.

Authors:  Wei-Xin Cai; Ru Qing Yu; Li Ma; Hong Zhang Huang; Li Wu Zheng; Roger Zwahlen
Journal:  Oncol Lett       Date:  2018-04-26       Impact factor: 2.967

2.  MicroRNA-34a directly targets high-mobility group box 1 and inhibits the cancer cell proliferation, migration and invasion in cutaneous squamous cell carcinoma.

Authors:  Shanshan Li; Chengqun Luo; Jun Zhou; Yong Zhang
Journal:  Exp Ther Med       Date:  2017-10-02       Impact factor: 2.447

3.  Computed tomography-based flap brachytherapy for non-melanoma skin cancers of the face.

Authors:  Emile Gogineni; Haocheng Cai; Dawn Carillo; Zaker Rana; Beatrice Bloom; Louis Potters; Hani Gaballa; Maged Ghaly
Journal:  J Contemp Brachytherapy       Date:  2021-02-18

4.  Recurrent Multiple Squamous Cell Carcinomas on the Scalp in a Patient with Juvenile Dermatomyositis.

Authors:  Yota Sato; Taku Fujimura; Yumi Kambayashi; Akira Tsukada; Takanori Hidaka; Kayo Tanita; Takahiro Haga; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2017-01-20

5.  Targeting the spliceosome for cutaneous squamous cell carcinoma therapy: a role for c-MYC and wild-type p53 in determining the degree of tumour selectivity.

Authors:  Lydia A Hepburn; Angela McHugh; Kenneth Fernandes; Garry Boag; Charlotte M Proby; Irene M Leigh; Mark K Saville
Journal:  Oncotarget       Date:  2018-05-01

6.  HOXA9 inhibits HIF-1α-mediated glycolysis through interacting with CRIP2 to repress cutaneous squamous cell carcinoma development.

Authors:  Liang Zhou; Yinghui Wang; Meijuan Zhou; Ying Zhang; Pengfei Wang; Xiaoxing Li; Jing Yang; Hongmei Wang; Zhenhua Ding
Journal:  Nat Commun       Date:  2018-04-16       Impact factor: 14.919

7.  HOXA9 Transcriptionally Promotes Apoptosis and Represses Autophagy by Targeting NF-κB in Cutaneous Squamous Cell Carcinoma.

Authors:  Shuo Han; Xue Li; Xiaoting Liang; Liang Zhou
Journal:  Cells       Date:  2019-10-31       Impact factor: 6.600

8.  Mutually exclusive lymphangiogenesis or perineural infiltration in human skin squamous-cell carcinoma.

Authors:  Julien Schaller; Hélène Maby-El Hajjami; Sylvie Rusakiewicz; Kalliopi Ioannidou; Nathalie Piazzon; Alexandra Miles; Déla Golshayan; Olivier Gaide; Daniel Hohl; Daniel E Speiser; Karin Schaeuble
Journal:  Oncotarget       Date:  2021-03-30

9.  MALAT1-KTN1-EGFR regulatory axis promotes the development of cutaneous squamous cell carcinoma.

Authors:  Ying Zhang; Lin Gao; Shudong Ma; Ji Ma; Yinghui Wang; Shanshan Li; Xia Hu; Shuo Han; Meijuan Zhou; Liang Zhou; Zhenhua Ding
Journal:  Cell Death Differ       Date:  2019-01-25       Impact factor: 15.828

10.  Possible Roles of Proinflammatory Signaling in Keratinocytes Through Aryl Hydrocarbon Receptor Ligands for the Development of Squamous Cell Carcinoma.

Authors:  Yota Sato; Taku Fujimura; Takanori Hidaka; Chunbing Lyu; Kayo Tanita; Shigeto Matsushita; Masayuki Yamamoto; Setsuya Aiba
Journal:  Front Immunol       Date:  2020-10-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.